US Broker Ratings

HealthStream, Inc. (HSTM) Stock Analysis: Exploring a 47% Potential Upside for Healthcare Investors

HealthStream, Inc. (NASDAQ: HSTM) stands out in the healthcare sector, specializing in health information services with a robust focus on software applications designed to enhance healthcare organizations’ efficiency. With a..

OrthoPediatrics Corp. (KIDS) Investor Outlook: Potential Upside of 35.84% Amid Strong Buy Ratings

OrthoPediatrics Corp. (NASDAQ: KIDS), a leader in the pediatric orthopedic medical device sector, presents a compelling opportunity for investors seeking exposure in the healthcare industry. With a robust market cap..

Avanos Medical, Inc. (AVNS) Stock Analysis: Navigating Challenges in the Healthcare Sector

Avanos Medical, Inc. (NYSE: AVNS), a prominent player in the healthcare sector, specializes in medical device solutions that cater to a diverse market, including North America and beyond. With a..

Oculis Holding AG (OCS) Stock Analysis: A Biotech with Over 124% Upside Potential

Oculis Holding AG (OCS), a Switzerland-based clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to treating ophthalmic diseases. With a market capitalization of $1.15..

Bicara Therapeutics Inc. (BCAX): Investor Outlook on a Biotech Stock with 82.71% Potential Upside

Bicara Therapeutics Inc. (NASDAQ: BCAX) has emerged as a noteworthy player in the biotechnology sector, captivating investors with its innovative approach to cancer treatment. As a clinical-stage biopharmaceutical company, Bicara..

Simulations Plus, Inc. (SLP) Investor Outlook: Assessing a 22.51% Potential Upside in Health Information Services

Simulations Plus, Inc. (NASDAQ: SLP), a significant player in the Health Information Services industry, is generating buzz among investors with its potential 22.51% upside, according to recent analyst ratings. As..

Nutex Health Inc. (NUTX) Stock Analysis: Evaluating a 51.86% Potential Upside in Healthcare Investment

Nutex Health Inc. (NUTX), a prominent player in the healthcare sector, is capturing investor attention with its compelling potential upside of 51.86%, as indicated by the average target price set..

Mind Medicine (MNMD) Stock Analysis: Biotech Leader Offers 114% Potential Upside

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is making waves in the biotechnology sector with its innovative approach to treating brain health disorders. Headquartered in New York, this clinical-stage biopharmaceutical company..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Exploring a 41.95% Potential Upside in the Biotech Sector

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) stands out in the healthcare sector with its innovative approach to tackling chronic endocrine and neurological diseases. This Chicago-based biopharmaceutical company has captured attention..

Akebia Therapeutics (AKBA): Analyzing 235% Potential Upside in the Healthcare Sector

For investors with an eye on the healthcare sector, Akebia Therapeutics, Inc. (NASDAQ: AKBA) presents a compelling case for potential portfolio growth. With a market capitalization of $427.24 million, this..

Replimune Group, Inc. (REPL)

⚠️ No article content returned.

..

Delcath Systems, Inc. (DCTH) Investor Outlook: Assessing a Potential 120% Upside

Delcath Systems, Inc. (NASDAQ: DCTH) is catching the eye of investors with a striking potential upside of 120.84%. This New York-based healthcare company is at the forefront of interventional oncology,..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a 517.98% Potential Upside in Biotech Innovations

Anavex Life Sciences Corp. (NASDAQ: AVXL), a promising player in the biotechnology sector, has piqued the interest of investors with an astonishing potential upside of 517.98%. This New York-based biopharmaceutical..

Beta Bionics, Inc. (BBNX) Investor Outlook: Strong Buy Ratings and Growth Potential in the Healthcare Sector

Beta Bionics, Inc. (NASDAQ: BBNX) is making waves in the healthcare sector with its innovative solutions aimed at improving the lives of individuals with diabetes. Specializing in medical devices, the..

Community Health Systems, Inc. (CYH) Stock Analysis: Evaluating a 25% Potential Upside

Community Health Systems, Inc. (NYSE: CYH), a key player in the healthcare sector, operates a network of general acute care hospitals throughout the United States. Despite the inherent volatility in..

Arcus Biosciences (RCUS) Investor Outlook: Analyzing a Potential 34.7% Upside Amid Biotech Volatility

Arcus Biosciences, Inc. (NASDAQ: RCUS), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its promising portfolio of cancer therapies. Based in Hayward, California, Arcus is focused..

Immatics N.V. (IMTX) Stock Analysis: Unveiling a 78% Potential Upside in Revolutionary Cancer Therapies

In the ever-evolving biotechnology landscape, Immatics N.V. (NASDAQ: IMTX) stands out as a beacon of innovation and potential. This German-based clinical-stage biopharmaceutical company focuses on pioneering T cell redirecting immunotherapies,..

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating Growth with a 15.1% Revenue Surge

InnovAge Holding Corp. (NASDAQ: INNV), a prominent player in the healthcare sector specializing in medical care facilities, is capturing investor attention with its impressive revenue growth of 15.1%. As a..

InMode Ltd. (INMD) Stock Analysis: Unpacking a 13% Potential Upside in the Medical Devices Sector

InMode Ltd. (INMD), an Israel-based leader in the healthcare sector, specializes in innovative medical devices, particularly those leveraging minimally invasive technologies. With a market capitalization nearing $1 billion, InMode has..

Ardelyx, Inc. (ARDX) Investor Outlook: Analyzing the 100% Potential Upside and Strong Buy Ratings

Ardelyx, Inc. (NASDAQ: ARDX) is capturing the attention of investors with its promising pipeline in the biotechnology sector. Specializing in the development and commercialization of innovative therapies for unmet medical..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds